Holen Sie sich die Stockscreener-App
15.76
1.48%
0.23
Schlusskurs vom Vortag:
$15.53
Offen:
$15.78
24-Stunden-Volumen:
1.56M
Relative Volume:
1.16
Marktkapitalisierung:
$1.18B
Einnahmen:
$254.91M
Nettoeinkommen (Verlust:
$-103.48M
KGV:
-11.23
EPS:
-1.4036
Netto-Cashflow:
$-148.35M
1W Leistung:
+7.95%
1M Leistung:
+30.79%
6M Leistung:
-8.37%
1J Leistung:
-25.13%
1-Tages-Spanne:
$15.39
$16.04
1-Wochen-Bereich:
$14.20
$16.30
52-Wochen-Spanne:
$10.95
$23.75
Schrodinger Inc Stock (SDGR) Company Profile
Firmenname
Schrodinger Inc
Sektor
Branche
Telefon
503-299-1150
Adresse
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
15.76 | 1.18B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
153.30 | 24.90B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
66.25 | 13.00B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
50.84 | 9.13B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
85.21 | 7.12B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
69.42 | 5.37B | 646.34M | -512.40M | 202.76M | -6.6871 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Neutral |
| 2025-08-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-14 | Eingeleitet | Barclays | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Neutral |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-13 | Eingeleitet | Berenberg | Buy |
| 2021-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-10-12 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-02 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-02 | Eingeleitet | Jefferies | Hold |
| 2020-03-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Schrodinger Inc Aktie (SDGR) Neueste Nachrichten
Schrodinger (SDGR) Issues Restricted Stock Units to New Employees - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Schrodinger Inc (SDGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
(SDGR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Schrodinger Inc (SDGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Schrodinger Inc (SDGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Schrodinger Inc (SDGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Schrodinger Inc (SDGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Schrodinger Inc (SDGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It - Benzinga
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM) - The Globe and Mail
SDGR Q1 2026 Earnings: EPS Misses Estimates as Company Focuses on Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
Schrödinger Finalizes Transition Terms for Former Commercial Chief - The Globe and Mail
Schrodinger finalizes separation agreement with former chief commercial officer - Investing.com
Schrodinger separation of Mannix Aklian as Chief Commercial Officer confirmed - TradingView
Severance package for ex-commercial chief at Schrödinger (NASDAQ: SDGR) - Stock Titan
(SDGR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Schrödinger’s Call Review: The Power of a Final Call - DualShockers
10 Top Tech Companies in Munich - Built In
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq - AD HOC NEWS
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook? - simplywall.st
Schrödinger, Inc. Hits Day High with Strong 7.34% Intraday Surge - MarketsMojo
Schrödinger, Inc. Hits Day High with Strong Intraday Performance, Up 7.39% - Markets Mojo
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth - Moomoo
Another Indie Matched Mina The Hollower's Review Scores This Week And No One Noticed - TheGamer
A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26 - GuruFocus
SDGR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Schrodinger Inc stock (US80655G1067): shares steady after May gains on Nasdaq - AD HOC NEWS
Schrödinger slides after early-stage trial data for cancer therapy - MSN
(SDGR) Risk Channels and Responsive Allocation - Stock Traders Daily
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets - Yahoo Finance
Stephens Investment Management Group LLC's Schrodinger Inc(SDGR) Holding History - GuruFocus
Schrodinger (SDGR) Issues Stock Options and RSUs to New Employees - GuruFocus
Schrodinger reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Schrodinger Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Schrödinger Announces Leadership Change Amid Maintained 2026 Outlook - TipRanks
Schrödinger, Inc. Reaffirms Earnings Guidance for the Second Quarter Ending June 30, 2026 and Fiscal Year Ending December 31, 2026 - marketscreener.com
Leadership change at Schrödinger (NASDAQ: SDGR) as CCO departs and outlook held - Stock Titan
My Top 3 Biotech Stocks for May 2026 - Yahoo Finance
Schrödinger Balances Growth and Losses in Earnings Call - TipRanks
SDGR: Improved funding and tech adoption are accelerating drug discovery and portfolio growth - TradingView
Schrodinger Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Schrodinger : SDGR - 24/7 Wall St.
Cheminformatics Market Size, Share | Growth Forecast [2034] - Fortune Business Insights
Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings - AD HOC NEWS
Rubric Capital and David Rosen disclose 9.28% position in Schrodinger (SDGR) - Stock Titan
(SDGR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Finanzdaten der Schrodinger Inc-Aktie (SDGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):